Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
复制标题
DOI：
10.1016/s0168-8227(98)00056-4
复制
发表时间：
1998-07-01
影响因子：
5.1
通讯作者：
Yamasaki, Y
中科院分区：
文献类型：
--
作者：
Kawamori, R;Matsuhisa, M;Yamasaki, Y
为评价吡格列酮对非胰岛素依赖型糖尿病（NIDDM）患者胰岛素抵抗的影响，对30例NIDDM患者进行了双盲安慰剂对照试验。21例受试者，3例单独饮食组，18例磺脲类（SU）组，口服吡格列酮30 mg，每日1次，连续12周。9名受试者，其中1名单独节食，8名服用抗抑郁药物，在12周内每天服用一次相应的安慰剂。在吡格列酮或安慰剂治疗3个月前后分别进行血糖（5.2 mmol/l）高胰岛素血症（1200 pmol/l）钳夹联合口服葡萄糖负荷（OGL），以确定胰岛素刺激的葡萄糖处理和内脏葡萄糖摄取（SGU）。两组患者的年龄、体重指数等特征无显著差异。吡格列酮使OGL前平均葡萄糖输注率（GIR）从8.2 +/- 2.2 mg/kg min提高到9.2 +/- 2.0 mg/kg min（平均值+/- SD， P =0.003），使SGU率从28.5 +/- 19.4提高到59.4 +/- 27.1% （P = 0.010）。安慰剂治疗后GIR和SGU均无显著变化。吡格列酮治疗组与安慰剂治疗组SGU变化差异有统计学意义（P = 0.042）。综上所述，吡格列酮可以通过提高SGU和外周葡萄糖摄取来改善NIDDM患者的胰岛素抵抗。(C) 1998爱思唯尔科学爱尔兰有限公司版权所有。
To evaluate the effect of pioglitazone on insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) patients, a double-blind placebo-controlled trial was carried out with 30 NIDDM patients. Twenty-one subjects, three on diet alone and 18 on sulfonylurea (SU), orally received 30 mg pioglitazone once daily for 12 weeks. Nine subjects, one on diet alone and eight on SU, received a matching placebo once daily for 12 weeks. Euglycemic (5.2 mmol/l) hyperinsulinemic (1200 pmol/l) clamp combined with an oral glucose load (OGL) was performed before and after 3-month treatment with pioglitazone or placebo to determine insulin-stimulated glucose disposal and splanchnic glucose uptake (SGU). No significant differences existed in the patients' characteristics, including age and body mass index, between the two study groups. The pioglitazone treatment increased the mean glucose infusion rate (GIR) prior to OGL from 8.2 +/- 2.2 to 9.2 +/- 2.0 mg/kg min (means +/- SD, P =0.003) and increased the SGU rate from 28.5 +/- 19.4 to 59.4 +/- 27.1% (P = 0.010). The placebo treatment produced no significant changes in either GIR or SGU after treatment. A significant difference (P = 0.042) was observed in change of SGU between the pioglitazone and placebo treatment groups. In conclusion, the results indicate that pioglitazone is effective for ameliorating insulin resistance in NIDDM by enhancing SGU as well as peripheral glucose uptake. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.